Cover Image
市場調查報告書

Fetzima(重度憂鬱症)- 預測與市場分析

Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 305479
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
Fetzima(重度憂鬱症)- 預測與市場分析 Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023
出版日期: 2014年05月30日 內容資訊: 英文 46 Pages
簡介

重度憂鬱症(MDD)是世界最常見的精神疾病之一。MDD市場競爭激烈,有30個以上的上市產品可用於患者的治療上。憂鬱症市場上,在主力產品(Eli Lilly的Cymbalta、大塚製薬/BMS的Abilify)專利即將到期,抗憂鬱症藥品的新產品(Lundbeck/武田薬品工業的Brintellix)及未來有望的後期階段開發平台產品即將上市的當下,市場正在大大變化中。

本報告提供MDD的治療藥物Fetzima之調查分析,提供疾病概要和治療指南,競爭情形,產品資訊,銷售額預測等相關之系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
  • 分類
  • 症狀和亞型
  • 預後
  • QOL

第4章 疾病的管理

  • 診斷和治療概要

第5章 競爭評估

  • 概要

第6章 Fetzima(Levomilnacipran)

  • 概要
  • 功效
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄

圖表

目錄
Product Code: GDHC420DFR

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

Fetzima (levomilnacipran) is an SNRI indicated for the treatment of MDD and is only available in the US. It gained FDA approval in July 2013 and was launched in December 2013. The product was developed by Forest (Actavis) following a partnership with Pierre Fabre. According to this agreement, Forest Laboratories is responsible for the clinical development and commercialization of Fetzima in the US and Canada, while Pierre Fabre is responsible for manufacturing and supplying the active pharmaceutical ingredient.

Scope

  • Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Fetzima including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Fetzima for the US from 2013 to 2023.
  • Sales information covered for the US.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Fetzima performance
  • Obtain sales forecast for Fetzima from 2013-2023 in the US.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms and Subtypes of Major Depressive Disorder
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Fetzima (Levomilnacipran)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed MDD Patients
    • 7.4.2. Percent of Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in this Study
  • 7.6. About the Authors
    • 7.6.1. Analyst
    • 7.6.2. Therapy Area Directors
    • 7.6.3. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10)
  • Table 2: Subtypes of Major Depressive Disorder
  • Table 3: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria
  • Table 4: Treatment Guidelines for Major Depressive Disorder
  • Table 5: Most Prescribed Drugs for MDD by Class in the 7MM and Australia, 2013
  • Table 6: Leading Treatments for MDD, 2013
  • Table 7: Product Profile - Fetzima
  • Table 8: Clinical Efficacy of Fetzima from its Three Pivotal Studies
  • Table 9: Safety of Fetzima - Five Most Frequently Reported Adverse Events in Clinical Studies
  • Table 10: Fetzima SWOT Analysis, 2014
  • Table 11: Global MDD Sales Forecasts ($m) for Fetzima, 2013-2023
  • Table 12: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons
  • Figure 2: Disease Management Model for Major Depressive Disorder
  • Figure 3: Major Depressive Disorder Treatment Algorithm
Back to Top